

# Xuan Gao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7395196/publications.pdf>

Version: 2024-02-01

16  
papers

231  
citations

1478505

6  
h-index

1125743

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

283  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. <i>OncImmunity</i> , 2022, 11, 2025668.	4.6	6
2	The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 834142.	4.8	4
3	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 799988.	4.8	7
4	Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, e799.	4.0	0
5	A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. <i>Oral Oncology</i> , 2022, 128, 105860.	1.5	4
6	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	5
7	Multi-omics analysis of locally advanced esophageal cell squamous carcinoma treated with radio-chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16106-e16106.	1.6	0
8	Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1110-e1124.	3.7	56
9	RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 677826.	2.8	7
10	The prevalence of HLA*LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA*LOH. <i>Human Mutation</i> , 2021, 42, 1254-1264.	2.5	2
11	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.	2.0	14
12	Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 806845.	2.8	6
13	An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. <i>Journal of Oncology</i> , 2021, 2021, 1-19.	1.3	2
14	CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 1620.	4.8	44
15	Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. <i>EBioMedicine</i> , 2019, 43, 261-269.	6.1	68
16	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6